METHOTREXATE REDUCES ADALIMUMAB IMMUNOGENICITY IN PATIENTS WITH SPONDYLOARTHRITIS: A RANDOMIZED CLINICAL TRIAL

被引：1
|
作者：
Ducourau, E. [1 ,2 ,3 ]
Rispens, T. [4 ]
Dernis, E. [5 ]
Le Guilchard, F. [6 ]
Andras, L. [6 ]
Perdriger, A. [7 ]
Lespessailles, E. [3 ]
Martin, A. [8 ]
Cormier, G. [9 ]
Armingeat, T. [10 ]
Devauchelle-Pensec, V. [11 ]
Solau-Gervais, E. [12 ]
Le Goff, B. [13 ]
de Vries, A. [14 ]
Piver, E. [15 ,16 ]
Ternant, D. [17 ,18 ]
Goupille, P. [1 ,2 ]
Mulleman, D. [1 ,2 ]
机构：
[1] Univ Francois Rabelais Tours, CNRS 7292, Rheumatol, Tours, France
[2] CHRU Tours, Rheumatol, Tours, France
[3] CHR Orleans, Rheumatol, Orleans, France
[4] Sanquin Res, Landsteiner Labs, Amsterdam, Netherlands
[5] CH Mans, Rheumatol, Le Mans, France
[6] CH Blois, Rheumatol, Blois, France
[7] CHRU Rennes, Rheumatol, Rennes, France
[8] CH St Brieuc, Rheumatol, St Brieuc, France
[9] CH la Roche Sur Yon, Rheumatol, La Roche Sur Yon, France
[10] CH St Nazaire, Rheumatol, St Nazaire, France
[11] CHRU Brest, Rheumatol, Brest, France
[12] CHRU Poitiers, Rheumatol, Poitiers, France
[13] CHRU Nantes, Rheumatol, Nantes, France
[14] Sanquin Diagnost Serv, Biol Lab, Amsterdam, Netherlands
[15] Univ Francois Rabelais Tours, Inserrn, U955, Biochem, Tours, France
[16] CHRU Tours, Biochem, Tours, France
[17] Univ Francois Rabelais Tours, Pharmacol Toxicol, CNRS 7292, Tours, France
[18] CHRU Tours, Pharmacol Toxicoloy, Tours, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.1527
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0349
引用
收藏
页码：335 / 336
页数：2
相关论文
共 50 条
  • [21] Efficacy of Adalimumab Compared With Methotrexate or Placebo Stratified by Baseline BMI in a Randomized Placebo-Controlled Trial in Patients With Psoriasis
    Prussick, Ronald
    Unnebrink, Kristina
    Valdecantos, Wendell C.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2015, 14 (08) : 864 - 868
  • [22] The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: A randomized clinical trial
    Menter, Alan
    Augustin, Matthias
    Signorovitch, James
    Yu, Andrew P.
    Wu, Eric Q.
    Gupta, Shiraz R.
    Bao, Yanjun
    Mulani, Parvez
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (05) : 812 - 818
  • [23] Microrna Expression Profiles Associated With Response To Adalimumab and Methotrexate Versus Methotrexate: A Placebo-Controlled Clinical Trial
    Krintel, Sophine B.
    Dehlendorff, Christian
    Hetland, Merete L.
    Horslev-Petersen, Kim
    Andersen, Klaus K.
    Junker, Peter
    Podenphant, Jan
    Ellingsen, Torkell
    Ahlqvist, Palle
    Lindegaard, Hanne M.
    Linauskas, Asta
    Schlemmer, Annette
    Dam, Mette Y.
    Hansen, Ib
    Horn, Hans Chr
    Jorgensen, Anette
    Raun, Johnny
    Ammitzboll, Christian G.
    Ostergaard, Mikkel
    Stengaard-Pedersen, Kristian
    Johansen, Julia S.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S374 - S375
  • [24] Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
    Combe, Bernard
    Kivitz, Alan
    Tanaka, Yoshiya
    van der Heijde, Desiree
    Simon, J. Abraham
    Baraf, Herbert S. B.
    Kumar, Uma
    Matzkies, Franziska
    Bartok, Beatrix
    Ye, Lei
    Guo, Ying
    Tasset, Chantal
    Sundy, John S.
    Jahreis, Angelika
    Genovese, Mark C.
    Mozaffarian, Neelufar
    Landewe, Robert B. M.
    Bae, Sang-Cheol
    Keystone, Edward C.
    Nash, Peter
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (07) : 848 - 858
  • [25] The prevalence and clinical effect of immunogenicity of TNF-α blockers in patients with axial spondyloarthritis
    Bornstein, G.
    Lidar, M.
    Langevitz, P.
    Fardman, A.
    Ben-Zvi, I.
    Grossman, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (02) : 228 - 232
  • [26] Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone: A Placebo-controlled Clinical Trial
    Sode, Jacob
    Krintel, Sophine B.
    Carlsen, Anting Liu
    Hetland, Merete L.
    Johansen, Julia S.
    Horsley-Petersen, Kim
    Stengaard-Pedersen, Kristian
    Ellingsen, Torkell
    Burton, Mark
    Junker, Peter
    Ostergaard, Mikkel
    Heegaard, Niels H. H.
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (01) : 53 - 61
  • [27] Clinical characteristics of Japanese patients with axial spondyloarthritis, and short-term efficacy of adalimumab
    Otsuka, Akiyo
    Morita, Mitsuhiro
    Yamada, Harumoto
    JOURNAL OF ORTHOPAEDIC SCIENCE, 2015, 20 (06) : 1070 - 1077
  • [28] Adalimumab with Methotrexate vs. Adalimumab Monotherapy in Psoriasis: First-Year Results of a Single-Blind Randomized Controlled Trial
    van der Kraaij, Gayle
    Busard, Celine
    van den Reek, Juul
    Menting, Stef
    Musters, Annelie
    Hutten, Barbara
    de Rie, Menno
    Ouwerkerk, Wouter
    Van Bezooijen, Sun-Jine
    Prens, Errol
    Rispens, Theo
    de Vries, Annick
    de Jong, Elke
    de Kort, Wim
    Lambert, Jo
    van Doorn, Martijn
    Spuls, Phyllis
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (09) : 2375 - +
  • [29] Efficacy of adalimumab in the treatment of preradiographic axial spondyloarthritis: Results of a 12-week, randomized controlled trial.
    Haibel, Hildrun
    Rudwaleit, Martin
    Heldmann, Frank
    Listing, Joachim
    Wong, Robert
    Kupper, Hartmut
    Braun, Juergen
    Sieper, Joachim
    ARTHRITIS AND RHEUMATISM, 2006, 54 (12): : 4044 - 4045
  • [30] Efficacy of adalimumab compared with methotrexate or placebo stratified by baseline BMI in a randomized, placebo-controlled trial
    Prussick, Ronald B.
    Unnebrink, Kristina
    Ghorayeb, Eric
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB233 - AB233
12345